IPOPI welcomes the grant of a marketing authorisation by the European Commission to XOLREMDITM, the first authorised treatment for patients with WHIM syndrome in the European Union.
WHIM stands for warts (skin growths), hypogammaglobulinemia (low levels of antibodies), infections, and myelokathexis (a condition in which immune cells are trapped in the bone marrow, preventing them from fighting infections).
Mavorixafor (XOLREMDI is the trade name) is indicated in patients 12 years of age and older for the treatment of WHIM syndrome to increase the number of circulating mature neutrophils, thereby helping the body to fight infections.
“This approval marks a significant moment for the WHIM syndrome community in Europe,” said Johan Prevot, Executive Director for IPOPI, the International Patient Organisation for Primary Immunodeficiencies. “For patients and families living with recurrent severe infections and the burden of an ultra-rare primary immunodeficiency, the availability of an authorised treatment represents meaningful progress. We will continue to champion the patient voice across Europe and beyond to ensure that national healthcare systems recognise the value of innovative treatments and provide equitable access to patients no matter where they live.”
